Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart failure

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

Amgen’s Aranesp disappoints in heart failure

Red blood cell stimulator no better than placebo

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

Novartis building

Novartis’ heart failure drug serelaxin meets targets

And FDA committee backs Signifor for Cushing's disease

- PMLiVE

Novo Nordisk posts ‘robust’ gains in sales and earnings

Diabetes drug Victoza and insulin analogue portfolio see strong growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links